15824260

Source:http://linkedlifedata.com/resource/pubmed/id/15824260

Download in:

Switch to

Custom View

Named Graph Language Inference

Statements in which the resource exists as a subject.
Predicate	Object
rdf:type	pubmed:Citation
lifeskim:mentions	umls-concept:C0013384, umls-concept:C0023570, umls-concept:C0030567, umls-concept:C0036866, umls-concept:C0205210, umls-concept:C0314603, umls-concept:C1521761, umls-concept:C2603343
pubmed:issue	4
pubmed:dateCreated	2005-4-12
pubmed:abstractText	Several factors, both clinical and genetic, may account for the risk of developing levodopa-induced peak-dose dyskinesias (PDD) in patients with Parkinson disease, but it is unclear how these factors interact for modulating the individual susceptibility for PDD.
pubmed:language	eng
pubmed:journal	http://linkedlifedata.com/resource/pubmed/journal/0372436
pubmed:citationSubset	AIM
pubmed:chemical	http://linkedlifedata.com/resource/pubmed/chemical/Antiparkinson Agents, http://linkedlifedata.com/resource/pubmed/chemical/Levodopa, http://linkedlifedata.com/resource/pubmed/chemical/Receptors, Dopamine D2
pubmed:status	MEDLINE
pubmed:month	Apr
pubmed:issn	0003-9942
pubmed:author	pubmed-author:AnnesiFerdinandaF, pubmed-author:AnnesiGraziaG, pubmed-author:ArabiaGennarinaG, pubmed-author:CarrideoSaraS, pubmed-author:Cirò-CandianoInnocenza CIC, pubmed-author:CivitelliDonatellaD, pubmed-author:De MarcoElvira VEV, pubmed-author:GambardellaAntonioA, pubmed-author:MessinaDemetrioD, pubmed-author:NicolettiGiuseppeG, pubmed-author:PugliesePierfrancescoP, pubmed-author:QuattroneAldoA, pubmed-author:SpadaforaPatriziaP, pubmed-author:TarantinoPatriziaP, pubmed-author:ZappiaMarioM
pubmed:issnType	Print
pubmed:volume	62
pubmed:owner	NLM
pubmed:authorsComplete	Y
pubmed:pagination	601-5
pubmed:dateRevised	2009-11-19
pubmed:meshHeading	pubmed-meshheading:15824260-Age of Onset, pubmed-meshheading:15824260-Aged, pubmed-meshheading:15824260-Antiparkinson Agents, pubmed-meshheading:15824260-Cohort Studies, pubmed-meshheading:15824260-DNA Mutational Analysis, pubmed-meshheading:15824260-DNA Repeat Expansion, pubmed-meshheading:15824260-Dose-Response Relationship, Drug, pubmed-meshheading:15824260-Dyskinesia, Drug-Induced, pubmed-meshheading:15824260-Female, pubmed-meshheading:15824260-Genetic Predisposition to Disease, pubmed-meshheading:15824260-Genetic Testing, pubmed-meshheading:15824260-Genotype, pubmed-meshheading:15824260-Humans, pubmed-meshheading:15824260-Levodopa, pubmed-meshheading:15824260-Male, pubmed-meshheading:15824260-Multivariate Analysis, pubmed-meshheading:15824260-Parkinson Disease, pubmed-meshheading:15824260-Polymorphism, Genetic, pubmed-meshheading:15824260-Predictive Value of Tests, pubmed-meshheading:15824260-Receptors, Dopamine D2, pubmed-meshheading:15824260-Sex Characteristics
pubmed:year	2005
pubmed:articleTitle	Sex differences in clinical and genetic determinants of levodopa peak-dose dyskinesias in Parkinson disease: an exploratory study.
pubmed:affiliation	Institute of Neurology, University ''Magna Graecia,'' Catanzaro, Italy.
pubmed:publicationType	Journal Article, Clinical Trial